Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.


NDAQ:INM - Post by User

Post by Steveminon Apr 14, 2021 3:30pm
125 Views
Post# 32994399

Inmed Webinar

Inmed WebinarApril 28th Inmed (Adams and Colwill) will be doing a "webinar" through Edison (remember, Inmed PAYS Edison for their coverage).

They say they are going to give an "overview of the company's recent operating and financial activiites followed by a brief Q&A session".

The timing of this makes no sense. They are due to report qtrly numbers just a couple of weeks after this, why not wait until then to regurgitate the same old BS?? Why a "brief" Q&A session? Well because these questions will all be pre determined -- there's no way either of these two guys will take an off the cuff question because they know precisely how pissed off their shareholders are and won't dare engage with them.
This is just an attempt to placate shareholders and make us feel like they are finally listening to  and answering questions that have gone unanswered for months (and years).

I have no idea what they could possibly says that hasnt been said already - unless they announce they are doing another cap raise!! With Adams, you just never know. And Colwill is so arrogant and patronizing that there's no way you'll get anything useful from him. This webinar will be a huge waste of time.....

HEY ADAMS - How about you focus on stopping this years long epic destruction of shareholder value?? It is time for you to go.


<< Previous
Bullboard Posts
Next >>